Objective: In this paper, we propose a robust, efficient, and automatic reconnection algorithm for bridging interrupted curvilinear skeletons in ophthalmologic images.
Methods: This method employs the contour completion process, i.e., mathematical modeling of the direction process in the roto-translation group to achieve line propagation/completion. The completion process can be used to reconstruct interrupted curves by considering their local consistency. An explicit scheme with finite-difference approximation is used to construct the three-dimensional (3-D) completion kernel, where we choose the Gamma distribution for time integration. To process structures in , the orientation score framework is exploited to lift the 2-D curvilinear segments into the 3-D space. The propagation and reconnection of interrupted segments are achieved by convolving the completion kernel with orientation scores via iterative group convolutions. To overcome the problem of incorrect skeletonization of 2-D structures at junctions, a 3-D segment-wise thinning technique is proposed to process each segment separately in orientation scores.
Results: Validations on 4 datasets with different image modalities show that our method achieves an average success rate of in reconnecting gaps of sizes from to , including challenging junction structures.
Conclusion: The reconnection approach can be a useful and reliable technique for bridging complex curvilinear interruptions.
Significance: The presented method is a critical work to obtain more complete curvilinear structures in ophthalmologic images. It provides better topological and geometric connectivities for further analysis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880863 | PMC |
http://dx.doi.org/10.1109/TBME.2017.2787025 | DOI Listing |
J Hosp Infect
September 2024
Infection Control Program and WHO Collaborating Centre, Geneva University Hospitals, Geneva, Switzerland; Infection Antimicrobials Modeling Evolution (IAME) U 1137, INSERM, Université Paris-Cité, Paris, France. Electronic address:
Background: Continuous fluid infusions delivered between therapies by piggy-back systems avoid disconnection and reconnection of central venous catheters (CVCs), thereby reducing opportunities for line contamination. However, the impact of continuous versus intermittent infusions on central line-associated bloodstream infections (CLABSIs) is unknown.
Aim: To investigate the effect of temporary infusion interruption and line disconnection, with or without use of a 70% isopropyl alcohol cap (IPA-C) on CLABSI rates in haematology patients.
Thromb Res
May 2024
Normandie Univ, UNIROUEN, U 1096, CHU Rouen, Department of Internal Medicine, F-76000 Rouen, France.
Background: Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a high mortality risk. Treatments aim to control bleeding and eradicate antibodies by immunosuppression. International recommendations rely on registers and international expert panels.
View Article and Find Full Text PDFEnviron Pollut
February 2024
Civil and Environmental Engineering, University of California Los Angeles, Los Angeles, USA. Electronic address:
Managed aquifer recharge (MAR) is a sustainable way of harvesting groundwater in water-stressed urbanized areas, where reclaimed wastewater or stormwater is applied on a large basin to infiltrate water into the groundwater aquifer naturally. This process could rapidly fluctuate the water table and move the capillary fringe boundary, and the change in flow dynamic and associated geochemical changes could trigger the release of sequestered pollutants, including per- and polyfluoroalkyl substances (PFAS), also known as 'forever chemicals', from the subsurface and capillary fringe. Yet, the potential of PFAS release from the subsurface and capillary zone during recharge events when the water table rapidly fluctuates has not been evaluated.
View Article and Find Full Text PDFN Engl J Med
May 2023
From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy).
Background: Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking.
Methods: We conducted a single-group trial in which we evaluated the temporary interruption of adjuvant endocrine therapy to attempt pregnancy in young women with previous breast cancer. Eligible women were 42 years of age or younger; had had stage I, II, or III disease; had received adjuvant endocrine therapy for 18 to 30 months; and desired pregnancy.
Neural Regen Res
October 2023
Laboratorio de Medicina Experimental "Dr. J. Toblli", Hospital Alemán; Consejo Nacional de Investigaciones Científicas y Técnicas - CONICET, CABA, Argentina; Rehabilitation Medicine Department, University of Minnesota, Twin Cities, MIN, USA.
Traumatic spinal cord injuries interrupt the connection of all axonal projections with their neuronal targets below and above the lesion site. This interruption results in either temporary or permanent alterations in the locomotor, sensory, and autonomic functions. Damage in the spinal tissue prevents the re-growth of severed axons across the lesion and their reconnection with neuronal targets.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!